Degarelix as a new antiangiogenic agent for metastatic colon cancer?

doi:10.3748/wjg.v19.i5.769

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4988)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

267

HTML

2575

Figures (1-1)

Sum=2935

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1099

Download

954

Sum=2053

Feb 7, 2013 (publication date) through Apr 22, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastroenterol. Feb 7, 2013; 19(5): 769-772
Published online Feb 7, 2013. doi: 10.3748/wjg.v19.i5.769

Open in New Tab Full Size Figure Download Figure

Figure 1 A tumor of the cecum. A: Kinetic of carcinoembryonic antigen (CEA) and follicle stimulating hormone (FSH) serum level; B: Representative images of contrast-enhanced ultrasonography performed before (left panel) and 15 d after (right panel) the beginning of the treatment by degarelix; C: Evaluation of vascularized surface area on contrast-enhanced ultrasonography performed before and 15 d after the beginning of the treatment by degarelix.

Citation: Ghiringhelli F, Isambert N, Ladoire S. Degarelix as a new antiangiogenic agent for metastatic colon cancer? World J Gastroenterol 2013; 19(5): 769-772
URL: https://www.wjgnet.com/1007-9327/full/v19/i5/769.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i5.769